Health Care·Biotechnology·$3.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.45 | N/A | -13.07% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.45 | N/A | -13.07% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management expressed caution regarding current market conditions. They emphasized the importance of their clinical pipeline but did not provide specific guidance.
Management did not provide specific revenue figures or guidance for the upcoming quarters.
The company is focusing on its ongoing clinical trials and product development.
The earnings report indicates that ACADIA PHARMACEUTICAL did not meet expectations for earnings per share, which contributed to a 1.74% decline in stock price. The lack of revenue figures and guidance may leave investors uncertain about the company's short-term outlook. Management's focus on clinical trials suggests they are prioritizing long-term growth over immediate financial performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SYSCO CORP
May 2, 2016